Abstract:SAR103168, a tyrosine kinase inhibitor of the pyrido [2,3-d] pyridimidine subclass, inhibited the kinase activities of the entire Src kinase family, Abl kinase, angiogenic receptor kinases (vascular endothelial growth factor receptor [VEGFR] 1 and 2), Tie2, platelet derived growth factor (PDGF), fibroblast growth factor receptor (FGFR) 1 and 3, and epidermal growth factor receptor (EGFR). SAR103168 was a potent Src inhibitor, with 50% inhibitory concentration (IC50) = 0.65 ± 0.02 nM (at 100 μM ATP), targeting the auto-phosphorylation of the kinase domain (Src(260-535)) and activity of the phosphorylated kinase. Phosphorylation of Src, Lyn and Src downstream signaling pathways (PYK2, P-130CAS, FAK, JNK and MAPK) were inhibited in a dose-dependent manner. SAR103168 inhibited the phosphorylation of STAT5 in KG1 cells and fresh cells from patients with acute myeloid leukemia (AML). SAR103168 inhibited proliferation and induced apoptosis in acute and chronic myeloid leukemic cells at nanomolar IC50. SAR103168 induced anti-proliferation of leukemic progenitors (CFU-L) from 29 patients with AML, and > 85% of AML patient samples were sensitive to SAR103168. These antagonist activities of SAR103168 were independent of FLT3 expression. SAR103168 treatment was effective in 50% of high-risk patient samples carrying chromosome 7 abnormalities or complex rearrangement. SAR103168 administration (intravenous or oral) impaired tumor growth and induced tumor regression in animals bearing human AML leukemic cells, correlating with potent inhibition of Src downstream signaling pathways in AML tumors. SAR103168 showed potent anti-tumor activity in SCID (severe combined immunodeficiency) mice bearing AML (KG1, EOL-1, Kasumi-1, CTV1) and chronic myeloid leukemia (CML) (K562) tumors. The combination of cytarabine and SAR103168 showed synergistic activity in AML and CML tumor models. These results highlight the therapeutic potential of SAR103168 in myeloid leukemias and support the rationale for clinical investigations.

A Pyridinesulfonamide Derivative FD268 Suppresses Cell Proliferation and Induces Apoptosis Via Inhibiting PI3K Pathway in Acute Myeloid Leukemia

Discovery of N-(2-chloro-5-(3-(pyridin-4-yl)-1H-pyrazolo[3,4-b] Pyridin-5-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide (FD274) As a Highly Potent PI3K/mTOR Dual Inhibitor for the Treatment of Acute Myeloid Leukemia

Design, Synthesis, and Evaluation of Pyrido.[3,4-B]pyrazin-2(1h)-one Derivatives As Potent FLT3 Inhibitors

Combination of RSK Inhibitor LJH-685 and FLT3 Inhibitor FF-10101 Promoted Apoptosis and Proliferation Inhibition of AML Cell Lines

Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.

Erianin Suppresses the Development of Acute Myeloid Leukemia Via PPARɑ and Regulating PI3K/AKT Signaling Pathways

Design, synthesis, and evaluation of pyrido.[3,4–b]pyrazin-2(1 H )-one derivatives as potent FLT3 inhibitors

Platycodin D induces apoptotic cell death through PI3K/AKT and MAPK/ERK pathways and synergizes with venetoclax in acute myeloid leukemia

Targeting PI3K, Mtor, ERK, and Bcl-2 Signaling Network Shows Superior Antileukemic Activity Against AML

Discovery of Potent and Selective PI3Kδ Inhibitors for the Treatment of Acute Myeloid Leukemia

A novel iheyamine A derivative L42 suppresses acute myeloid leukemia via dual regulation of the PI3K/AKT/FOXO3a axis and TNF signaling pathway

Blockade of de novo pyrimidine biosynthesis triggers autophagic degradation of oncoprotein FLT3-ITD in acute myeloid leukemia

Synthesis and biological evaluation of 4-(4-aminophenyl)-6-methylisoxazolo[3,4-b] pyridin-3-amine covalent inhibitors as potential agents for the treatment of acute myeloid leukemia

Bioisosteric Replacements of the Indole Moiety for the Development of a Potent and Selective PI3Kδ Inhibitor: Design, Synthesis and Biological Evaluation

SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias

Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia

PX-478 induces apoptosis in acute myeloid leukemia under hypoxia by inhibiting the PI3K/AKT/mTOR pathway through downregulation of GBE1

Discovery of highly potent p53-MDM2 antagonists and structural basis for anti-acute myeloid leukemia activities.

Discovery of novel selective phosphodiesterase‐1 inhibitors for the treatment of acute myelogenous leukemia

Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor

Rational design and optimization of novel 4-methyl quinazoline derivatives as PI3K/HDAC dual inhibitors with benzamide as zinc binding moiety for the treatment of acute myeloid leukemia